| All patients N = 159 | Potential Undertreatment N = 103 | According to guideline treatment N = 56 | P-value |
---|---|---|---|---|
CHF | 101 (63.5) | 63 (61.2%) | 38 (67.9%) | 0.402 |
Hypertension | 54 (34) | 41 (39.8%) | 13 (23.2%) | 0.080 |
History of stroke/TIA | 30 (18.9) | 10 (9.7%) | 20 (35.7%) | 0.000 |
Vascular disease | 36 (22.6) | 21 (20.4%) | 15 (26.8%) | 0.357 |
DM | 8 (5.0) | 6 (5.8%) | 2 (3.6%) | 0.714 |
Anemia (Hemoglobin< 12/13) | 33 (20.8) | 22 (21.4%) | 11 (19.64%) | 0.799 |
IHD/ACS | 14 (8.8) | 10 (9.7%) | 4 (7.1%) | 0.772 |
Hyperthyroidism | 22 (13.8) | 16 (15.5%) | 6 (10.7%) | 0.400 |
Cardiomyopathy | 5 (3.1) | 3 (2.9%) | 2 (3.6%) | 1.000 |
Cardiomegaly | 43 (27.0) | 23 (22.3%) | 20 (35.7%) | 0.070 |
Increased LV wall thickness | 5 (3.1) | 1 (1.0%) | 4 (7.1%) | 0.052 |
LVH | 18 (11.3) | 12 (11.7%) | 6 (10.7%) | 0.859 |
LA enlargement | 10 (6.3) | 6 (5.8%) | 4 (7.1%) | 0.742 |
Liver disease (LFT > 3XULN) | 11 (6.9%) | 6 (5.8%) | 5 (8.9%) | 0.461 |
History of bleeding | 5 (3.1%) | 2 (1.9%) | 3 (5.4%) | 0.236 |